February 2025
Hookipa Pharma Cancels Planned Merger with Poolbeg Pharma
Hookipa Pharma, Poolbeg Pharma, merger cancellation, biotech deal termination
HOOKIPA Pharma Terminates Acquisition Talks with Poolbeg Pharma
biotech merger, acquisition termination, HOOKIPA Pharma, Poolbeg Pharma, immunotherapeutics, rare disease
Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans
Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A
Biotech M&A Heats Up: Cosette’s $430M Mayne Pharma Acquisition and Industry-Wide Stock Buybacks
Biotech acquisitions, pharmaceutical mergers, stock repurchase programs, women’s health, dermatology, market consolidation
AstraZeneca to acquire FibroGen’s China unit for $160M
China, AstraZeneca, FibroGen, FibroGen ‘s, roxadustat
BridgeBio’s Attruby Gains FDA Approval, Challenging Pfizer’s Tafamidis in ATTR-CM Treatment
Attruby, acoramidis, BridgeBio, ATTR-CM, tafamidis, Pfizer, FDA approval, transthyretin stabilizer, cardiomyopathy
Incyte and Genesis Therapeutics Forge $620M AI-Driven Drug Discovery Partnership
Artificial intelligence, drug discovery, small molecule therapeutics, GEMS platform, oncology, immunology, strategic collaboration
Trump’s Healthcare Nominees Pledge to Divest Industry Investments Amid Controversy
Trump administration, healthcare appointments, NIH, CMS, divestment, industry ties, Jay Bhattacharya, Mehmet Oz, Robert F. Kennedy Jr.
AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat
AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry
Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns
Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption